367500-88-7 Usage
General Description
Tert-butyl 4-(4-hydroxypiperidin-1-yl)piperidine-1-carboxylate is a chemical compound with the molecular formula C16H30N2O3. It is a derivative of piperidine and contains a hydroxyl group attached to a piperidine ring. tert-butyl 4-(4-hydroxypiperidin-1-yl)piperidine-1-carboxylate is often used in pharmaceutical research and drug development as a building block for the synthesis of various bioactive molecules. Its unique structure and functional groups make it potentially useful for the development of drugs targeting specific receptors or biological pathways. Additionally, the tert-butyl group provides steric hindrance and stability to the molecule, making it suitable for various synthetic applications in medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 367500-88-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,7,5,0 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 367500-88:
(8*3)+(7*6)+(6*7)+(5*5)+(4*0)+(3*0)+(2*8)+(1*8)=157
157 % 10 = 7
So 367500-88-7 is a valid CAS Registry Number.
367500-88-7Relevant articles and documents
3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS
-
Paragraph 0322, (2021/04/23)
The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.
TRPV4 ANTAGONISTS
-
Page/Page column 38, (2011/10/13)
The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
